February 11, 2014 at 9:53 AM
SUMMIT, NJ - Equinox Summit hosted one of the largest fundraising rides as part of "Cycle For Survival", a national non-profit program benefitting Memorial Sloan Kettering Cancer Center battle against rare cancers.
Each of the 320 participating teams generated pledges of at least $1,000, but that threshold was smashed, with the event generating more than $1,000,000 in donations.
According to the National Institute of Health, a rare cancer is one with a prevalence of fewer than 200,000 affected individuals in the United States. Diseases defined as "rare cancers" include brain, pancreatic, thyroid and stomach cancers; leukemia and lymphoma; all pediatric cancers, and others. More than half the people diagnosed with cancer have a rare form of the disease.
Cycle For Survival was founded by the late Jennifer Goodman Linn and husband Dave, as a single event at Equinox. Linn, a native of Livingston, was diagnosed with soft-tisue sarcoma in 2004, and succumbed to the disease in July, 2011.
Cycle For Survival has now grown, with Equinox as its national partner, to events in 14 cities across the country. Since its inception in 2007, the event has raised $42.6 million, and contributed to 85 clinical trials. In 2013 alone, there were 12,000 cyclers on 2,800 bikes that combined to raise $14 million. One-hundred percent of the funds raised go directly to MSKCC, and are allocated within six months after each event.
The entire Equinox Summit facility was transformed into a giant spin class studio, with morning and afternoon sessions consisting of 160 teams each. Teams were decked out in their official team gear, ranging from matching t-shirts to full cycling regalia. There were refueling stations, a massage area, a photo booth, and tables with donation information. Equinox also produces event-specific wearables, with all proceeds from the sale of clothing also donated to the cause. To learn more about Cycle For Survival, visit https://secure2.convio.net/mskcc/site/SPageServer/?pagename=cycle_for_survival.